ARQT vs HCM

ARQT's Piotroski F-Score of 1/9 indicates severe financial distress, with weak profitability, negative ROE and ROA, and no dividend, signaling poor operational health. Despite strong revenue growth of 81.5% YoY and a forward P/E of 17.79, the company remains unprofitable with a negative profit margin of -4.29% and no intrinsic value or Graham Number available. Insider selling totaling $5.12M in the last six months, including significant sales by the CEO and directors, reinforces bearish sentiment. The stock trades at a premium to its fundamentals, with a Price/Sales of 7.50 and Price/Book of 14.81, suggesting overvaluation relative to earnings and book value. Analysts' strong_buy consensus appears disconnected from the underlying financial deterioration.

HCM presents a contradictory profile: it is fundamentally undervalued based on deterministic metrics, with a Piotroski F-Score of 5/9 (Stable) and a current price ($15.24) well below both its Graham Number ($20.72) and Intrinsic Value ($18.55). However, the company's operational health is concerning, characterized by negative revenue growth (-16.5%) and a severe collapse in earnings (-98.1% YoY). While the balance sheet is exceptionally strong with very low debt and high liquidity, the core business is currently unprofitable at the operating level. The investment case relies on a turnaround or a catalyst to realize the analyst target price of $22.85.